血尿激酶型纖溶酶原激活劑mRNA水平表達與乳腺癌及其淋巴結轉移的關系_《中國普外基礎與臨床雜志》

作者：

熊俊 , 張錦輝 , 鄭啟昌

華中科技大學同濟醫學院附屬協和醫院普外科（武漢430022）;

關鍵詞：

尿激酶型纖溶酶原激活劑乳腺癌熒光定量逆轉錄酶鏈式反應轉移

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

【摘要】目的研究血尿激酶型纖溶酶原激活劑（uPA）mRNA水平表達與乳腺癌及淋巴結轉移的關系及其臨床意義。
方法應用熒光定量RT-PCR方法，檢測 60例乳腺良、惡性腫瘤患者血中uPA mRNA水平的表達，分析其與乳腺癌及其淋巴結轉移的關系。
結果uPA mRNA表達在18例良性腫瘤患者中16例為陰性，2例為低表達。在42例乳腺癌患者中，無淋巴結轉移的20例中18例為陽性，其中1例為高表達， 5例為中度表達，12例為低表達，另2例為陰性；有淋巴結轉移的22例均為陽性，其中16例為高表達，5例為中度表達，1例為低表達。乳腺良、惡性腫瘤患者血中uPA mRNA表達差異有顯著性意義（P＜0.05）；乳腺癌患者中無淋巴結轉移者uPA mRNA的表達強度明顯低于有淋巴結轉移者（P＜0.05）。
結論血中uPA mRNA在乳腺癌中的表達明顯高于良性腫瘤，其表達強度與乳腺癌淋巴結轉移明顯相關，可為臨床分期及后續治療提供依據。

引用本文： 熊俊,張錦輝,鄭啟昌. 血尿激酶型纖溶酶原激活劑mRNA水平表達與乳腺癌及其淋巴結轉移的關系. 中國普外基礎與臨床雜志, 2005, 12(3): 241-243. doi: 復制

1.	Harbeck N, Kates RE, Gauger K, et al. Urokinasetype plasminogen activator (uPA) and its inhibitor PAII: novel tumorderived factors with a high prognostic and predictive impact in breast cancer [Ｊ]. Thromb Haemost, 2004; 91(3)∶450.
2.	Thomssen C, Janicke F, Harbeck N. Clinical relevance of prognostic factors in axillary nodenegative breast cancer [Ｊ]. Onkologie, 2003; 26(5)∶438.
3.	李亞芬.乳腺癌腫瘤標志物的研究和臨床應用進展 [Ｊ]. 中國普外基礎與臨床雜志， 2002; 9(5)∶298.
4.	Hsu DW, Efird JT, HedleyWhyte ET. Prognostic role of urokinasetype plasminogen activator in human gliomas [Ｊ]. Am J Pathol, 1995; 147(1)∶114.
5.	熊俊，鄭啟昌，宋自芳. 尿激酶型纖溶酶原激活劑mRNA在胃癌組織中的表達及其意義 [Ｊ]. 中國普外基礎與臨床雜志， 2004; 11(2)∶116.
6.	Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI1 and HER2 status provide independent and complementary information on patient outcome in nodenegative breast cancer [Ｊ]. J Clin Oncol, 2003; 21(6)∶1022.
7.	Guo Y, Pakneshan P, Gladu J, et al. Regulation of DNA methylation in human breast cancer. Effect on the urokinasetype plasminogen activator gene production and tumor invasion [Ｊ]. J Biol Chem, 2002; 277(44)∶41571.
8.	Harbeck N, Schmitt M, Kates RE, et al. Clinical utility of urokinasetype plasminogen activator and plasminogen activator inhibitor1 determination in primary breast cancer tissue for individualized therapy concepts [Ｊ]. Clin Breast Cancer, 2002; 3(3)∶196.
9.	Hemsen A, Riethdorf L, Brunner N, et al. Comparative evaluation of urokinasetype plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells [Ｊ]. Int J Cancer, 2003; 107(6)∶903.
10.	Qin W, Zhu W, WagnerMann C, et al. Nipple aspirate fluid expression of urokinasetype plasminogen activator, plasminogen activator inhibitor1, and urokinasetype plasminogen activator receptor predicts breast cancer diagnosis and advanced disease [Ｊ]. Ann Surg Oncol, 2003; 10(8)∶948.
11.	Qin W, Zhu W, WagnerMann C, et al. Association of uPA, PAT1, and uPAR in nipple aspirate fluid (NAF) with breast cancer [Ｊ]. Cancer J, 2003; 9(4)∶293.
12.	Manders P, TjanHeijnen VC, Span PN, et al. Predictive impact of urokinasetype plasminogen activator: plasminogen activator inhibitor type1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer [Ｊ]. Cancer Res, 2004; 64(2)∶659.
13.	Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified highrisk according to urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3 424) [Ｊ]. Cancer Res, 2002; 62(16)∶4617.

1. Harbeck N, Kates RE, Gauger K, et al. Urokinasetype plasminogen activator (uPA) and its inhibitor PAII: novel tumorderived factors with a high prognostic and predictive impact in breast cancer [Ｊ]. Thromb Haemost, 2004; 91(3)∶450.
2. Thomssen C, Janicke F, Harbeck N. Clinical relevance of prognostic factors in axillary nodenegative breast cancer [Ｊ]. Onkologie, 2003; 26(5)∶438.
3. 李亞芬.乳腺癌腫瘤標志物的研究和臨床應用進展 [Ｊ]. 中國普外基礎與臨床雜志， 2002; 9(5)∶298.
4. Hsu DW, Efird JT, HedleyWhyte ET. Prognostic role of urokinasetype plasminogen activator in human gliomas [Ｊ]. Am J Pathol, 1995; 147(1)∶114.
5. 熊俊，鄭啟昌，宋自芳. 尿激酶型纖溶酶原激活劑mRNA在胃癌組織中的表達及其意義 [Ｊ]. 中國普外基礎與臨床雜志， 2004; 11(2)∶116.
6. Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI1 and HER2 status provide independent and complementary information on patient outcome in nodenegative breast cancer [Ｊ]. J Clin Oncol, 2003; 21(6)∶1022.
7. Guo Y, Pakneshan P, Gladu J, et al. Regulation of DNA methylation in human breast cancer. Effect on the urokinasetype plasminogen activator gene production and tumor invasion [Ｊ]. J Biol Chem, 2002; 277(44)∶41571.
8. Harbeck N, Schmitt M, Kates RE, et al. Clinical utility of urokinasetype plasminogen activator and plasminogen activator inhibitor1 determination in primary breast cancer tissue for individualized therapy concepts [Ｊ]. Clin Breast Cancer, 2002; 3(3)∶196.
9. Hemsen A, Riethdorf L, Brunner N, et al. Comparative evaluation of urokinasetype plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells [Ｊ]. Int J Cancer, 2003; 107(6)∶903.
10. Qin W, Zhu W, WagnerMann C, et al. Nipple aspirate fluid expression of urokinasetype plasminogen activator, plasminogen activator inhibitor1, and urokinasetype plasminogen activator receptor predicts breast cancer diagnosis and advanced disease [Ｊ]. Ann Surg Oncol, 2003; 10(8)∶948.
11. Qin W, Zhu W, WagnerMann C, et al. Association of uPA, PAT1, and uPAR in nipple aspirate fluid (NAF) with breast cancer [Ｊ]. Cancer J, 2003; 9(4)∶293.
12. Manders P, TjanHeijnen VC, Span PN, et al. Predictive impact of urokinasetype plasminogen activator: plasminogen activator inhibitor type1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer [Ｊ]. Cancer Res, 2004; 64(2)∶659.
13. Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified highrisk according to urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3 424) [Ｊ]. Cancer Res, 2002; 62(16)∶4617.

《中國普外基礎與臨床雜志》

血尿激酶型纖溶酶原激活劑mRNA水平表達與乳腺癌及其淋巴結轉移的關系

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

血尿激酶型纖溶酶原激活劑mRNA水平表達與乳腺癌及其淋巴結轉移的關系

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料